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S358 Poster Session IIThese findings suggest that the reduced GvHD was not due to re-
duced function, altered subsets or relative deficiency of allogeneic
donor T cells but from an alteration of in vivo trafficking of
IFNgR-/- T cells compared to WT T cells. We further demon-
strated that the IFNgR-mediated signaling in alloreactive donor T
cells was required for expression of CXCR3 which has been impli-
cated in trafficking of T cells to areas of inflammation and target or-
gans, commonly known to be the sites of GvHD. In addition,
overexpression of CXCR3 in IFNgR-/- T cells rescued the
GvHD-inducing function of IFNgR-/- T cells. CXCR3-/- T cells
and pharmacological approaches using inhibitors of IFNgR signal-
ing recapitulated the anti-GvHD (and pro-GvL) effects seen in
IFNgR-/- T cells after allo-HSCT. Thus, the IFNgR-CXCR3
axis represents a promising therapeutic target for future efforts to
mitigate GvHD while maintaining GvL after allo-HSCT.
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ULTRA LOW-DOSE IL-2 MEDIATED EXPANSION OF REGULATORY T
CELLS AS GVHD PROPHYLAXIS FOR RECIPIENTS OF ALLOGENEIC HEMA-
TOPOIETIC STEM CELLS
Kennedy-Nasser, A.A.1, Ku, S.1, Melenhorst, J.2, Barrett, J.2,
Hazrat, Y.1, Durett, A.G.1, Foster, A.1, Savoldo, B.1, Yvon, E.1,
Heslop, H.E.1, Carrum, G.1, Kamble, R.T.1, Brenner, M.K.1,
Krance, R.A.1, Bollard, C.M.1 1Baylor College of Medicine, Houston,
TX; 2National Institutes of Health, Bethesda, MD
CD4+ CD25+ FoxP3+ regulatory T cells (Tregs) may prevent graft-
versus-host disease (GvHD) after allogeneic hematopoietic stem cell
transplantation (HSCT). We and others have previously used low-
dose IL-2 therapy in HSCT recipients in an attempt to enhance an-
titumor immunity and observed low rates of GvHD. Retrospective
analysis showed that patients who received IL-2 had higher levels
of FoxP3+ T cells than controls, suggesting that IL-2 may preferen-
tially expand Tregs in vivo, thereby preventing GvHD.We therefore
initiated a prospective phase II clinical trial to evaluate the efficacy
and toxicity of ultra low-dose (ULD) IL-2 injections following allo-
geneic HSCT to promote Treg expansion in vivo and prevent signif-
icant GvHD. As our control population, we evaluated Treg
reconstitution post HSCT in patients who did not receive IL-2.
Twelve patients have been treated with ULD IL-2 (100,000 to
200,000 IU/m2 3x weekly SC) post HSCT starting before day 30
and continuing for 6 to 12 weeks. Median age at time of HSCT
was 14 years (range, 6y to 56y). Eight patients received matched sib-
ling donor transplants and four received alternative donor trans-
plants with Campath 1-H for in vivo T-cell depletion. By flow
cytometry, all patients demonstrated a rise in the percentage of
CD4+ CD25+ FoxP3+ Tregs by 6 weeks following initiation of IL-2
therapy with a mean of 5.2% (range, 0 to 11.0%) pre IL-2 to
a mean of 13.2% (range, 4.4 to 31.1%) post treatment. Compared
to the control HSCT population, a significant rise in Treg percent-
ages was found at 1 and 3 months post HSCT in patients receiving
IL-2 (1 month: 12.8% vs. 6.8%, p 5 0.008; 3 months: 10.5% vs.
6.2%, p5 0.02). Functional analyses of CD4+ CD25bright cells dem-
onstrated suppression ofmixed lymphocyte reactions. There were no
grade 3 or 4 toxicities associated with ULD IL-2. No patients on
study developed grade III-IV acute GvHD, compared to 4/31
(13%) of controls. IL-2 recipients also retained T cells reactive to vi-
ral and tumor antigens, and only 25%of study patients versus 61%of
the control group developed viral infections. Hence, ULD IL-2 is
well-tolerated, expands a CD4+ CD25+ FoxP3+ Treg population in
vivo, andmay be associated with a lower incidence ofGvHDand viral
infections; the study continues to evaluate these putative benefits.417
INTERLEUKIN-15 (IL-15) ADMINISTRATION INCREASES GRAFT VERSUS
LEUKEMIA ACTIVITY IN RECIPIENTS OF HAPLOIDENTICAL HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Sauter, C., Bailey, C., Biswas, C., Budak, T., Panis, M., Alpdogan, O.
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
The success of haploidentical (HI) hematopoietic stem cell trans-
plantation (HSCT), suggests that graft-versus leukemia (GVL) ef-
fect might have a substantial role in this transplant modality.Rigorous T-cell depletion (TCD) of the graft decreases the occur-
rence of graft-versus-host disease (GVHD) in HI-HSCT, however
this results in immunodeficiency and high disease relapse rate, espe-
cially in patients with resistant or residual leukemia. Therefore, en-
hancingGVL activity of HSCTwithout increasingGVHD is crucial
for improving the outcome of haploidentical transplant.
Post-transplant IL-15 administration is shown to enhance im-
mune reconstitution, particularly donor-derived NK and CD8+ T
cell populations in murine models. We evaluated the efficacy of
IL-15 for enhancing GVL effect in recipients of HI-HSCT. For de-
veloping clinically relevant haploidentical transplant models, differ-
ent hybrid mice with B6 background that share the same haplotype
(H2Kb) are used for our murine haploindentical transplant experi-
ments. Lethally irradiated B6D2F1/J (H2Kb/d) mice are trans-
planted with B6CBAF1/J (H2Kb/k) TCD bone marrow (BM) and
T cells at varying doses. Some animals were also given P815 tumor
cells on the day of transplant. Administration of IL-15 significantly
increased the numbers of CD8+ T and NK cells in the spleen and
BM in the T cell depleted model at post-transplant day 28. Infusion
of very low dose haploidentical T cells (1x104) with TCD-BM re-
sulted in a conflicting effect on immune reconstitution, i.e. increased
T cell numbers, and decreased NK cell population. Post-transplant
IL-15 administration also changed this immune reconstitution pat-
tern and significantly increased both T and NK cell numbers in re-
cipients of HI-HSCT. In P815 challenged mice that were
transplanted with very low dose T cell added TCD-BM, IL-15 ad-
ministration significantly increased anti-tumor activity of the graft
and improved survival without increasing GVHD. This effect was
observed when IL-15 administration was given at a later time point
rather than immediately following transplantation, possibly allowing
for more donor cell engraftment and T cell proliferation to take
place. IL-15 administration without T cell infusion did not result
in any survival improvement. We conclude that in our experimental
HI transplant models, IL-15 administration augments anti-tumor
activity of the HI-HSCT without increasing GVHD risk, and this
effect requires presence of donor derived T cells.418
COMPARISON OF MYCOPHENOLATE MOFETIL (MMF) VERSUS METHO-
TREXATE (MTX) FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DIS-
EASE: RESULTS OF A META-ANALYSIS
Kharfan-Dabaja, M.A.1, Mhaskar, R.2, Pidala, J.A.3, Perkins, J.B.3,
Djulbegovic, B.2, Kumar, A.2 1American University of Beirut, Beirut,
Lebanon; 2Univ. of South Florida, College of Medicine, Tampa, FL;
3Moffitt Cancer Center, Tampa, FL
Background: morbidity and mortality resulting from acute and
chronicGVHD remains themost serious challenge to wider applica-
bility of T-cell replete allogeneic HCT for otherwise incurable he-
matologic diseases. Developing effective regimens acute GVHD
(aGVHD) prophylaxis is of vital importance due to lack of effective
treatments, mainly when refractory to corticosteroids. Conflicting re-
sults have been observed when comparing, directly or indirectly,
MMF-based against MTX-based regimens for aGVHD prophylaxis.
Methods: a systematic and comprehensive literature search was per-
formed using MEDLINE databases from 1966 to 07/31/2011. All
completed prospective-randomized (phase II or III) clinical trials
(RCT) or retrospective non-randomized comparisons (NRC) pub-
lished as a full manuscript were eligible for inclusion, but data pub-
lished only in abstract form was not. Outcomes extracted from
selected studies (RCT 5 2, retrospective NRC 5 2) included:
time-to-ANC engraftment, time-to-platelets engraftment, inci-
dences of grade II-IV aGVHD and chronic GVHD (cGVHD), inci-
dence of severe mucositis, frequency of pain control requirement,
frequency of total parenteral nutrition (TPN) use, relapse rate, inci-
dence of non-relapse mortality (NRM) and overall survival (OS).
Results: pooled analysis shows that use of MMF, for aGVHD pro-
phylaxis, results in significantly faster platelets engraftment (pooled
hazard ratio (HR)5 1.15 (95%CI, 1.08,1.23; p\0.0001)), a lower in-
cidence of severe mucositis (pooled risk ratio (RR) 5 0.48 (95%CI,
0.32, 0.71; p 5 0.0003)), and less use of TPN (pooled RR 5 0.52
(95%CI, 0.34, 0.80; p5 0.003)) or narcotics for pain control (pooled
risk ratio5 0.76 (95%CI, 0.63, 0.91; p5 0.002)) compared toMTX.
Poster Session II S359There was no difference, however, between MMF and MTX in inci-
dence of grade II-IV aGVHD (pooled RR 5 0.99 (95%CI, 0.83,
1.18; p 5 0.87)), incidence of cGVHD (pooled RR 5 1.01 (95%CI,
0.83, 1.22; p 5 0.95)), relapse risk (pooled RR 5 0.97 (95%CI,
0.68,1.38; p 5 0.86)), NRM (pooled RR 5 0.91 (95%CI, 0.60, 1.37;
p5 0.64)) or OS (pooled HR5 0.83 (95%CI, 0.58, 1.20; p5 0.33)).
Conclusion: critical appraisal of available evidence appears limited/
weak to recommend one particular agent, MMF or MTX, to com-
bine with a calcineurin inhibitor as the preferred aGVHD prophy-
laxis regimen. A large randomized controlled trial that compares
MMF and MTX is needed to address this issue. But, identifying
the most optimal doses and schedules of administration of MMF
and MTX is necessary beforehand.419
THE CNS IN ACUTE GVHD: DEVELOPMENT AND EFFECTS
Hartrampf, S.1,4, Dudakov, J.A.1, Johnson, L.K.2, Smith, O.M.1,
Tsai, J.1, Singer, N.V.1, West, M.L.1, Hanash, A.1, Liu, B.F.3,
Toth, M.3, Van Den Brink, M.R.M.5 1Memorial Sloan-Kettering Cancer
Center, New York, NY; 2Memorial Sloan-Kettering Cancer Center, New
York, NY; 3Cornell University, Weill Medical College, New York, NY;
4Ludwigs-Maximilans-Universitaet, Munich, Germany; 5Memorial
Sloan-Kettering Cancer Center, New York, NY
Graft-versus-host disease (GVHD) is a severe complication of mul-
tiple organ systems in allogeneic hematopoietic stem cell transplanta-
tion (HSCT). An association between neurological complications and
GVHDhas been reported in patients after allogeneicHSCT. In amu-
rine MHC-disparate allogeneic transplantation model (BM and T
cells from C57BL/6 into lethally irradiated BALB/c) we studied
whether the CNS is a target organ of acute GVHD.
CNS infiltrating lymphocytes were isolated frombrains after com-
plete perfusion of the animals. We found increasing numbers of
CNS-infiltrating donor derived CD4 and CD8 alloreactive T cells
on day 7, 14, and 21 (p\0.001) in brains from allo-HSCT recipients,
but almost none in syngeneic transplanted controls. The majority of
infiltrating lymphocytes were effector memory T cells
(CD44highCD62Llow). P-selectin-glycoprotein-1, Lymphocyte-
function-associated-antigen-1 and a4-Integrin were broadly and
CXCR-3 was less frequently expressed, while Lymphocyte-Peyer-
patch-adhesion-molecule was absent, the latter distinguishing
CNS infiltrating T cells from peripheral T cells.
Histological analysis and immunohistochemistry for CD3 and
CD4 in situ showed infiltration of Cortex, Hippocampus, Basal gan-
glia, Thalamus, Hypothalamus, Cerebellum, andMedulla oblongata
in allogeneicHSCT recipients, consistent with lymphocyticmultifo-
cal meningoencephalitis. Syngeneic transplanted controls showed no
pathology and T cells were virtually undetectable (p\0.01). Apopto-
tic cell death by TUNEL staining was only observed in allogeneic
transplanted controls.
We performed behavioral tests 14 to 20 days after HSCT to test
whether these findings were associated with cognitive deficits. Mice
were tested before the onset of severe GVHD. We found no differ-
ences between allogeneic- versus syngeneic- or non-transplanted
mice in locomotor activity, motor coordination, strength and neuro-
muscular function. However, allogeneic transplanted animals demon-
strated increased anxious behavior and decreased exploratory activity
(p\0.01). Importantly, spatial learning was impaired in allogeneic
transplanted animals as compared to both controls (p\0.0001).
In conclusion, we observed in our experimental GVHD models
that allo-HSCT recipients incur a lymphocytic meningoencephalitis
during the early stages of acute GVHD, which is associated with sig-
nificant infiltration of donor effectormemoryT cells in the CNS and
certain cognitive defects, such as spatial memory loss.420
TEN YEARS EXPERIENCE OF HOME-CARE DURING THE NEUTROPENIC
PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION
Ringden, O.1, Remberger, M.1, Wikstrom, M.2, Holmberg, K.2,
Eriksson, B.2, Fransson, K.2, Milovsavljevic, R.2, Omazic, B.1,
Svenberg, P.1, Mattsson, J.1, Svahn, B.-M.2 1Karolinska Institutet, Kar-olinska Univ. Hospital Huddinge, Stockholm, Sweden; 2Karolinska Uni-
versity Hospital Huddinge, Stockholm, Sweden
After allogeneic hematopoietic stem-cell transplantation (HSCT),
patients living within one and a half hours’ driving distance to the
unit were given the option of treatment at home after HSCT. An ex-
perienced nurse visited the patient every morning and a phone-call
from a physician was given in the afternoon.
One-hundred and forty-six patients treated at home during the
neutropenic phase were compared to matched hospital controls,
coming from outside Stockholm. Because good oral nutrition was
correlated to reduced acuteGVHD, oral intake was intensified in pa-
tients treated in the hospital from September 2006 (new controls).
We compared four groups; old home-care (before September
2006, n 5 76), new home-care (from September 2006, n 5 70),
old (n 5 76) and new controls (n 5 70).
The cumulative incidence of acute GVHDgrades II – IV was 15%
in the old home-care group, which was significantly lower as op-
posed to 32 – 44% in the new home-care group (p\0.001) and the
two control groups (p\0.03). Cumulative incidence of chronic
GVHD was between 35 and 41% in the four groups.
Transplant-related mortality was between 10 and 24% in the
four groups (n.s.). No patient died at home. Relapse probability
was similar in the four groups. Oral nutrition (kcal/kg/day) dur-
ing the first three weeks was significantly worse in the old con-
trols, as opposed to all other groups (p\0.01). Among the old
controls, oral nutrition was median 18.5 kcal/kg/day, as opposed
to 23.6 kcal/kg/day in the new controls (p 5 0.002). Oral nutri-
tion (p 5 0.02) and days at home (p 5 0.005) were correlated to
low grade of acute GVHD. The new home-care patients spent
fewer days at home (p 5 0.002). In multivariate analysis,
GVHD grades 0-I was associated with home care (HR 2.46, p
5 0.02), days spent at home (HR 0.92, p 5 0.005), but not to
oral nutrition (HR 0.98, p 5 0.13). Despite improved oral intake
in patients treated in the hospital more recently, acute GVHD
did not decrease. The old home-care patients had a decreased
risk of acute GVHD, which probably is due to a long time spent
at home.
Five-year survival was 61% in the home-care group as compared
to 49% in the controls (p 5 0.07).
Conclusion: Home care is safe. Home care and many days spent at
home were correlated to a low risk of acute GVHD.421
SYSTEMIC AND HEPATIC THIOL REDOX DYSREGULATION IN GRAFT VER-
SUS HOST DISEASE
Kanathezhath, B.1,2, Shenvi, S.1, Johl, A.1, Manmohan, R.1,
Bhandhal, M.K.3, Oh, D.3, Zhou, A.1, Kuypers, F.A.1,
Walters, M.C.1,2, Ames, B.N.1,3, Suh, J.1 1Children’s Hospital Oakland
Research Institute, Oakland, CA; 2Children’s Hospital and Research Cen-
ter Oakland, Oakland, CA; 3University of California Berkeley, Berkeley,
CA
Graft-versus-host disease (GVHD) is mediated by a series of path-
ophysiological events that follow transplant conditioning and are
amplified by cellular effectors and inflammatory pathways. In addi-
tion, GVHD increases oxidative stress and alters the redox environ-
ment. Whether redox dysregulation in itself potentiates the tissue
injury of GVHD is unknown. We hypothesized that redox pertuba-
tion is a proximal event that precedes target organ injury in GVHD.
To explore this, we appliedmass-spectrometry based thiol redoxme-
tabolomics to analyze the plasma and hepatic sulfur amino acid
(SAA) and thiol oxidation states in several well characterized murine
models of GVHD (Allo) and compared to syngeneic (Syn) controls,
at multiple time-points post-transplantation. Of the 38 amino-acid
metabolites profiled, significant depletion of plasma glutathione
(GSH) redox potential was noted in Allo (-127.36 16mV) compared
to Syn [158.1618 mV (p5 0.04)] mice as early as day +4 post- trans-
plantation. This change in GSH redox state was not reflected in the
cysteine (Cys/CySS) system, the principal redox couple in plasma. By
day +14 post-transplantation, further decline in plasma GSH was
noted in Allo mice while normalization of this metabolite was seen
in Syn controls. The total hepatic GSH concentration in Allo
